MTR

Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards

Retrieved on: 
Tuesday, March 26, 2024
Tao, Internal medicine, Professor, Patient, Pulmonology, Executive Committee, Drug, Therapy, Chairperson, Sensation, Genentech, NSW, St George's Hospital, Harvard University, MTR, Pediatrics, Stanford University, Teaching hospital, Critical care, Outline of health sciences, KCP, Neuroinflammation, UCSF, Research, Acquisition, University, Management, MPH, Drug development, Atopic dermatitis, Entrepreneurship, Critical Care Medicine (journal), Adolescence, Contact dermatitis, Science, Division, KRYS, Pharmaceutical industry

FREMONT, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the appointment of Hubert Chen, M.D., MPH, as Chief Medical Officer, effective March 21, 2024. Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development. At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.

Key Points: 
  • Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development.
  • At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.
  • Prior to Krystal, Dr. Chen was at Genentech/Roche where he held clinical leadership positions across both early and late-stage development.
  • To support the ongoing strategic development of the Attobody platform and advancement of the Company’s emerging pipeline candidates, Attovia has established Clinical and Scientific Advisory Boards comprised of biopharmaceutical industry veterans and academic experts.

ViewSonic Adds New Microsoft Teams Rooms Bundles to its Meeting Space Solutions

Retrieved on: 
Monday, March 25, 2024
Software, Technology, Hardware, Data Management, Microsoft, Trusted Platform Module, Noise, TPM, MTR, ViewSonic, Workflow, System, Business Line, Human, Video game

ViewSonic Corp., a leading global provider of visual solutions, announced the launch of its Microsoft Teams Rooms Meeting Space Solutions.

Key Points: 
  • ViewSonic Corp., a leading global provider of visual solutions, announced the launch of its Microsoft Teams Rooms Meeting Space Solutions.
  • The ViewSonic® Meeting Space Solutions integrate hardware and software features, and are designed to optimize collaboration, video conferencing, improve productivity, and streamline communications.
  • These Microsoft Teams Rooms certified bundles from ViewSonic offer a complete, singular solution that can be easily scaled based on needs and meeting space requirements.
  • “We’re excited to bring Microsoft Teams Rooms certified bundles from ViewSonic to the market and offering our customers and partners a comprehensive meeting solution,” said Jeff Muto, Business Line Director at ViewSonic.

Mesa Royalty Trust Announces Trust Income for March 2024

Retrieved on: 
Tuesday, March 19, 2024
Energy, Other Energy, Oil, Gas, Form, San Juan Basin, Risk, Trustee, MTR, Life insurance

Mesa Royalty Trust (the “Trust”) (NYSE: MTR) announced today the Trust income distribution for the month of March 2024.

Key Points: 
  • Mesa Royalty Trust (the “Trust”) (NYSE: MTR) announced today the Trust income distribution for the month of March 2024.
  • Unitholders of record on March 29, 2024 will receive distributions amounting to $0.027776761 per unit, payable on April 30, 2024.
  • No income was received in March 2024 from any other working interest owner.
  • The working interest owners alone control historical operating data, and handle receipt and payment of funds relating to the royalty properties and payments to the Trust for the related royalty.

EQS-News: Telefónica Deutschland: Confident FY24 outlook based on good business momentum and ‘Accelerated Growth & Efficiency Plan’

Retrieved on: 
Wednesday, March 13, 2024
BTS, Traction, Investment, Growth, Churn, Carbon accounting, ESG, Coorilose Geevarghese, FCF, Commercial, ARPU, EUR, PPE, MSR, MTR, AGM, CO2, Tax, Income tax, Fitch, OPEX, OIBDA, Environment, VDSL, Lithium

The renowned connect magazine awarded Telefónica Deutschland’s O2 network with a ‘very good’ rating for the fourth time in a row despite tougher test criteria each year.

Key Points: 
  • The renowned connect magazine awarded Telefónica Deutschland’s O2 network with a ‘very good’ rating for the fourth time in a row despite tougher test criteria each year.
  • In parallel, Telefónica Deutschland is continuously pursuing its ESG commitments to make a substantial contribution to a sustainable digital future.
  • O2 postpaid churn confirmed a low rate of 1.1% in Q4 23 (1.2% in Q4 22) respective 1.0% in FY23.
  • Telefónica Deutschland consistently delivered growth throughout FY23 with robust commercial traction and sustained healthy financial performance.

Mesa Royalty Trust Announces Trust Income for February 2024

Retrieved on: 
Friday, February 16, 2024
Oil, Gas, Energy, San Juan Basin, Risk, Form, MTR, Trustee, Life insurance

Mesa Royalty Trust (the “Trust”) (NYSE: MTR) announced today the Trust income distribution for the month of February 2024.

Key Points: 
  • Mesa Royalty Trust (the “Trust”) (NYSE: MTR) announced today the Trust income distribution for the month of February 2024.
  • Unitholders of record on February 29, 2024 will receive distributions amounting to $0.008739141 per unit, payable on April 30, 2024.
  • No income was received in February 2024 from any other working interest owner.
  • The working interest owners alone control historical operating data, and handle receipt and payment of funds relating to the royalty properties and payments to the Trust for the related royalty.

HKG epiTherapeutics Limited Announces the Launch of its MetaGen Mutations Panel

Retrieved on: 
Wednesday, January 31, 2024
Smoke, COMT, MTHFR, Single-nucleotide polymorphism, DNA, MTR, Gene, Ageing, MTRR, DNA methylation, Health, Cancer, Vaccine

HONG KONG, Jan. 31, 2024 /PRNewswire/ -- HKG epiTherapeutics Limited ("HKG" or "the Company"), a commercial-stage biotech company developing novel tools for the early detection of cancer and promoting healthy aging, announced today the launch of its new product, MetaGen Mutations Panel, an innovative genetic methylation test, which evaluates specific genes that offer individuals unparalleled insights into their genetic profiles and their effects on health and aging.

Key Points: 
  • These genes play a key role in the body's methylation processes, influencing a wide array of biological functions – from DNA methylation and repair and detoxification – to neurotransmitter synthesis.
  • "The launch of our MetaGen Mutations Panel is a true testament to HKG's commitment to empowering individuals with detailed health insights, enabling informed decisions about nutrition, lifestyle and health management strategies," said Prof. Szyf, HKG's Founder and CEO.
  • The launch of this new product marks a significant step towards this goal, offering a holistic and scientifically grounded tool for personalized health."
  • The MetaGen Mutations Panel is now available for purchase online, shipped directly to customers for easy access to health insights.

AudioCodes and Kramer Partner to Deliver Complete Solution for Microsoft Teams Rooms

Retrieved on: 
Tuesday, January 30, 2024
Microsoft, AudioCodes, MTR, Partnership, Human, DSPS, AI, AUDC, Microsoft Teams, Video game

LOD, Israel, Jan. 30, 2024 /PRNewswire/ --

Key Points: 
  • The partnership brings together AudioCodes' expertise in Microsoft Teams Room solutions, management tools and AI-powered meeting analytics, with Kramer's expertise in innovative audio-visual solutions.
  • The collaboration provides system integrators with a uniquely comprehensive solution for Microsoft Teams meeting spaces to support their customers' hybrid workplace strategies.
  • AudioCodes (NASDAQ: AUDC), a leader in advanced communications software and AI and Kramer, a pioneer in audio-visual products and solutions have announced a new partnership to deliver complete Microsoft Teams Room (MTR) solutions.
  • This strategic partnership integrates AudioCodes' Microsoft Teams Room products with Kramer's innovative audio-visual solutions.

Silicon Valley's Finest Startups Set to Ride HKSTP Elevator Pitch Competition 2024 to Asia and the World Stage

Retrieved on: 
Friday, January 19, 2024
Silicon, MTR, HKSTP, IMF, Partnership, Ecosystem, Property technology, Epic, HK, International Commerce Centre, Fintech, Growth

72 global finalists to qualify from four regional semi-finals for the Hong Kong Grand Finale with possible US$5 million in venture funding, US$240,000 in cash prizes, plus partnership opportunities

Key Points: 
  • Hong Kong's leading incubator HKSTP aims to elevate the best startups across FinTech, PropTech and MobilityTech and fast track their journey to global success.
  • The Silicon Valley Region Semi-Final for EPiC 2024 is an ideal opportunity for Silicon Valley's best innovators to propel themselves to investors and partners in Asia and onto the world stage.
  • All EPiC 2024 finalists will have an opportunity to have up to US$5 million investment from the HKSTP Corporate Venture Fund.
  • HKSTP successfully completed the first-ever Silicon Valley Elevator Pitch Competition 2024 (EPiC) Region Semi-Final on January 17 and 18, 2024, with 20 of the Valley’s finest innovators selected to fly to Hong Kong on 26 April 2024 for the EPiC 2024 Grand Finale.

Mesa Royalty Trust Announces Trust Income for January 2024

Retrieved on: 
Thursday, January 18, 2024
Oil, Gas, Energy, MTR, San Juan Basin, Risk, Trustee, Form, Life insurance

Mesa Royalty Trust (the “Trust”) (NYSE: MTR) announced today the Trust income distribution for the month of January 2024.

Key Points: 
  • Mesa Royalty Trust (the “Trust”) (NYSE: MTR) announced today the Trust income distribution for the month of January 2024.
  • Unitholders of record on January 31, 2024 will receive distributions amounting to $0.025185860 per unit, payable on April 30, 2024.
  • No income was received in January 2024 from any other working interest owner.
  • The working interest owners alone control historical operating data, and handle receipt and payment of funds relating to the royalty properties and payments to the Trust for the related royalty.

NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement for Development and Production of Actinium-225 (Ac-225)-based Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Solid Tumors

Retrieved on: 
Wednesday, January 3, 2024
Oncology, Health, Other Health, General Health, Radiology, Pharmaceutical, Biotechnology, MTR, FRCR, Licensure, Olaf Scholz, Multimedia, Research, FRCP, Nuclear medicine, MD, Cancer, Doctor of Philosophy, Patient, Diagnosis, Radiopharmaceutical, NorthStar, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20240103888457/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240103888457/en/
    Under the agreement, NorthStar will support the development of select Curadh radiopharmaceutical targets by preparing and distributing Curadh patient doses of n.c.a.
  • Ac-225 for its ongoing clinical studies and, upon approval, may manufacture and supply radiopharmaceuticals for commercial use.
  • The new agreement also provides Curadh access to NorthStar’s integrated radiopharmaceutical development and manufacturing organization to support development and commercialization of future radiopharmaceutical diagnostic and therapeutic agents.
  • Ac-225, using the advanced, environmentally preferable electron accelerator technology that today supports routine production of the therapeutic radioisotope copper-67 (Cu-67).